LOX and cancer: Although there are no approved dual COX/LOX drugs but clinical trials have shown to be very promising, dual COX-2/LOX inhibitors have also demonstrated an ability to inhibit cancer cell proliferation, with tepoxalin and licofelone being two drugs under clinical trials that have displayed anti-inflammatory effects and are less ulcerogenic than indomethacin.